Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Comparison of the combination of 1, 3‐bis(2‐chloroethyl)‐l‐nitrosourea (BCNU) and vincristine with two dose schedules of 5‐(3,3‐dimethyl‐l‐triazino) imidazole 4‐carboxamide (DTIC) in the treatment of disseminated malignant melanoma
Cancer, Volume 35, No. 2, Year 1975
Notification
URL copied to clipboard!
Description
One hundred twenty patients with inoperable metastatic malignant melanoma were randomly allocated to treatment with either a combination of BCNU 150 mg/m2 and vincristine 2 mg/m2 given every 30 days, or one of two regimens of DTIC: 300 mg/m2/day × 6 or 100 mg/m2/8 hours × 18 given every 30 days. Eight of the 51 (16%) patients who were originally treated with the BCNU and vincristine combination had 50% or more objective tumor regression, compared to 6 out of 25 (24%) patients treated with daily injections of DTIC, and 6 out of 21 (29%) patients treated with DTIC injections every 8 hours. The median duration of response to the BCNU and vincristine combination was 60 days, and the median duration of survival from initiation of treatment was 6.5 months in the responders and 3.3 months in the nonresponders. The median duration of response was 90 and 100 days for the daily and 8‐hour regimens of DTIC respectively, and the median duration of survival from commencement of treatment was 8.5 months for the responders and 3.5 months for the nonresponders. None of the 43 patients who failed to respond to the initial treatment program or whose disease progressed after initial improvement responded to the alternate treatment regimen. Copyright © 1975 American Cancer Society
Authors & Co-Authors
Cooper, Miles Robert
Unknown Affiliation
Blom, Johannes
Unknown Affiliation
Falkson, Geoffrey G.
Unknown Affiliation
Maurice, Pierre A.
Unknown Affiliation
Brunner, Kurt W.
Unknown Affiliation
Glidewell, Oliver J.
Unknown Affiliation
Holland, James F.W.
Unknown Affiliation
Statistics
Citations: 37
Authors: 7
Affiliations: 1
Identifiers
Doi:
10.1002/1097-0142(197502)35:2<368::AID-CNCR2820350211>3.0.CO;2-C
ISSN:
0008543X
Research Areas
Cancer